A kind of sirpα fusion protein and preparation method and use thereof

A fusion protein and composition technology, applied in the field of fusion proteins, can solve the problems of effectiveness, safety and production cost limitations, and achieve the effects of reducing production costs, improving phagocytosis, and enhancing affinity

Active Publication Date: 2021-11-05
上海高菲生物科技有限公司
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, the current molecular design of SIRPα still has limitations in effectiveness, safety and production cost.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of sirpα fusion protein and preparation method and use thereof
  • A kind of sirpα fusion protein and preparation method and use thereof
  • A kind of sirpα fusion protein and preparation method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0040] Experimental Example 1 Preparation of SIRPα fusion protein of the present invention

[0041] Such as figure 1 Shown is a schematic structural diagram of the SIRPα fusion protein of the present invention. SIRPα-Fc and SIRPα-Fc-Fc fusion proteins are composed of human IgG1 Fc region (SEQ ID NO. 2), human IgG4 Fc region (SEQ ID NO. 3) , human IgG1 Fc-Fc or human IgG4 Fc-Fc fused with the N-terminal V domain (variable region domain) of human SIRPα (SEQ ID NO. 1) to obtain a fusion protein.

[0042] Among them, the same human SIRPα domain is connected to the human IgG4 Fc region containing the hinge stabilizing S288P mutation that prevents the formation of disulfide bonds in the chain, and SIRPα-Fc (Fc is human IgG4 Fc) and SIRPα-Fc-Fc (Fc It is human IgG4 Fc-Fc) fusion protein, and its sequences are respectively shown in SEQ ID NO. 8 and SEQ ID NO. 9.

[0043] All fusion proteins described above were produced by overlapping PCR using standard molecular biology techniques ...

experiment example 2

[0058] Experimental example 2 The binding effect of SIRPα-lgG4-Fc fusion protein of the present invention on CD47

[0059] (1) Western blot experiment of binding of SIRPα-lgG4-Fc fusion protein of the present invention to CD47

[0060] Mix the above purified fusion protein with different concentrations (equal ratio increase, 0.1nM, 1nM, 10nM, 100nM) with purified CD47 protein (10ng, Abcam) and protein A sepharose beads in PBS solution, 4 degrees Overnight, the immune complexes were pelleted by centrifugation and run on SDS-PAGE gel electrophoresis. Finally, CD47 protein levels were quantified by Western blot assay. Wherein, the amount of CD47 added was directly used as a control.

[0061] Such as figure 2 As shown, it is the western blotting diagram (IP, Immunoprecipitation, immunoprecipitation experiment; WB, Western Blotting, immunoblotting experiment) of the SIRPα-lgG4-Fc fusion protein of the present invention that carries out IP-WB experiment, it can be seen that with...

experiment example 3

[0067] Experimental example 3 Induction of the phagocytosis effect of the SIRPα-lgG4-Fc fusion protein of the present invention in vitro

[0068] (1) Preparation of M1 macrophages

[0069] Human M1 macrophages were prepared from monocytes obtained from normal healthy human donors (human peripheral blood mononuclear cells were provided by StemCelltechnologies). Monocytes were differentiated into macrophages by culturing in special differentiation medium (supplied by StemCell technologies) supplemented with M-CSF (Macrophage Colony-Stimulating Factor) (20 ng / mL), Specific steps are as follows:

[0070] Monocytes were differentiated into macrophages by culturing in RPMI 1640-based differentiation medium for 6-10 days. The medium was supplemented with the following components: 10% heat-inactivated human AB serum, 1% GlutaMax, 1% penicillin and streptomycin (purchased from GIBCO LifeTechnologies).

[0071] One day before the measurement of phagocytosis, IFN-γ (Interferon-γ, γ-in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a SIRPα fusion protein and its preparation method and application. The fusion protein comprises: the V domain of SIRPα, and an Fc segment with effector function; the V domain comprises: the amino acid sequence of SEQ ID No. 1. The Fc segment includes: the constant region of human IgG1 or IgG4 antibody. The fusion protein of the present invention enhances the affinity between SIRPα and CD47, the half-life in vivo, and the effector function mediated by the Fc segment, and can strongly induce the phagocytosis of macrophages against various tumor cells.

Description

technical field [0001] The present invention relates to a fusion protein, in particular to a SIRPα fusion protein and its preparation method and application. Background technique [0002] Evasion of the immune system is one of the hallmarks of tumors. In recent years, using the body's original immune response to fight against tumors has gradually become a new treatment strategy. According to the chronological order of the application of different mechanisms of therapy, it mainly includes non-specific immune stimulation, immune checkpoint monoclonal antibody, adoptive cell reinfusion, monoclonal T Cell receptor therapy, CD47 monoclonal antibody, tumor vaccine, etc., are among the most promising therapies both in the experimental stage and in clinical application. Normally, macrophages can infiltrate the tumor body and their antitumor effects can be exploited to benefit the patient. [0003] CD47, also known as Integrin Associated Protein (IAP), is a member of the immunoglob...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00A61K38/17A61K47/42A61P35/00
CPCA61K38/00A61P35/00C07K14/4702C07K2319/30
Inventor 孙建成于志恒
Owner 上海高菲生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap